Compare SON & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SON | MIRM |
|---|---|---|
| Founded | 1899 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.4B |
| IPO Year | N/A | 2019 |
| Metric | SON | MIRM |
|---|---|---|
| Price | $42.88 | $63.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | $56.83 | ★ $87.55 |
| AVG Volume (30 Days) | ★ 878.5K | 560.0K |
| Earning Date | 10-22-2025 | 11-04-2025 |
| Dividend Yield | ★ 4.99% | N/A |
| EPS Growth | ★ 116.52 | N/A |
| EPS | ★ 6.30 | N/A |
| Revenue | ★ $7,114,053,000.00 | $471,794,000.00 |
| Revenue This Year | $45.04 | $53.78 |
| Revenue Next Year | N/A | $19.91 |
| P/E Ratio | $6.74 | ★ N/A |
| Revenue Growth | ★ 67.86 | 53.66 |
| 52 Week Low | $38.65 | $36.88 |
| 52 Week High | $52.77 | $78.55 |
| Indicator | SON | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 62.04 | 34.17 |
| Support Level | $40.39 | $63.66 |
| Resistance Level | $41.76 | $66.77 |
| Average True Range (ATR) | 0.85 | 2.93 |
| MACD | 0.18 | -0.69 |
| Stochastic Oscillator | 96.71 | 6.51 |
Over its 100-year-plus history, Sonoco Products has steadily assembled a diverse portfolio of industrial and consumer packaging product offerings such as flexible and rigid plastics, reels and spools, pallets, and composite cans. The company serves a variety of consumer and industrial end markets throughout North America. Sonoco has raised its dividend each year for more than 40 years.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.